Clinical pharmacology information in summaries of product characteristics and package inserts

Clinical Pharmacology and Therapeutics

Volumn 82, Issue 5, 2007, Pages 566-571

  Arguello, B ^a   Fernandez Llimos, F ^a,b  

^a UNIVERSITY OF GRANADA   (Spain)

^b UNIVERSITY OF LISBON   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; DRUG INFORMATION; DRUG PACKAGING; EUROPE; HEALTH CARE QUALITY; HEALTH SERVICE; PRESCRIPTION; PRIORITY JOURNAL; SCORING SYSTEM;

CLINICAL PHARMACY INFORMATION SYSTEMS; DRUG INFORMATION SERVICES; DRUG LABELING; EUROPEAN UNION; HUMANS; PHARMACOLOGY, CLINICAL; SPAIN; UNITED STATES;

EID: 35448997390     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/sj.clpt.6100198     Document Type: Article

References (27)

1. Enwistle, V.A. & Watt, I.S. Disseminating information about health care effectiveness: a survey of consumer health information services. Qual. Health Care 7, 124-129 (1998).
2. Vander Stichele, R.H., Vandierendonck, A., De Vooght, G., Reynvoet, B. & Lammertyn, J. Impact of benefit messages in patient package inserts on subjective drug perception. Drug Inf. J. 26, 201-208 (2002).
3. European Council. Council Directive 92/27/EEC of 31 March 1992 on the labeling of medicinal products for human use and on package leaflets. Official Journal L 113, 0008-0012 (1992).
4. European Commission. A Guideline on the Readability of the Label and Package Leaflet of Medicinal Products for Human Use (September 1998), (Pharmaceutical Committee, European Commission, Brussels, 1998).
5. G10 Medicines Group. High level group on innovation and provision of medicines in the European Union. Recommendations for action G10 medicines report, http://ec.europa.eu/enterprise/phabiocom/docs/g10-medicines.pdf (2002). Accessed 27 October 2006.
6. Bjerrum, L. & Foged, A. Patient information leaflets - helpful guidance or a source of confusion? Pharmacoepidemiol. Drug Saf. 12, 55-59 (2003).
7. Raynor, D.K. & Britten, N. Medicine information leaflets fail concordance test. BMJ 322, 1541 (2001).
8. Raynor, D.K. & Knapp, P. Do patients see, read, and retain the new mandatory medicines information leaflets? Pharm. J. 264, 268-270 (2000).
9. Fuchs, J., Hippius, M. & Schaefer, M. Analysis of German package inserts. Int. J. Clin. Pharmacol. Ther. 44, 8-13 (2006).
10. Directive 2004/27/EC of the European Parliament and of the Council of 31 March 2004 amending Directive 2001/83/EC on the Community code relating to medicinal products for human use. Official Journal L. 136, 34-57 (2004).
11. European Commission. Notice to applicants. Guideline on Summary of Product Characteristics, http://ec.europa.eu/enterprise/pharmaceuticals/ eudralex/vol-2/c/spcguidrev1-oct2005.pdf (2005). Accessed 27 October 2006.
12. Bergk, V., Haefeli, W.E., Gasse, C., Brenner, H. & Martin-Facklam, M. Information deficits in the summary of product characteristics preclude an optimal management of drug interactions: a comparison with evidence from the literature. Eur. J. Clin. Pharmacol. 61, 327-335 (2005).
13. San Miguel, T., Martinez, J.A. & Vargas, E. Food-drug interactions in the summary of product characteristics of proprietary medicinal products. Eur. J. Clin. Pharmacol. 61, 77-83 (2005).
14. Fusier, I., Tollier, C. & Husson, M.C. Infovigilance: reporting errors in official drug information sources. Pharm. World Sci. 27, 166-169 (2005).
15. National Institute for Statistics. http://www.ine.es. Accessed 18 September 2006.
16. Prescriptions invoiced to the National Health Service. Prescriptions invoiced to the National Health Service. Anuario de la Comunidad del Medicamento 2006 (Contenidos, Madrid, 2006).
17. Spyker, D.A. et al. Assessment and reporting of clinical pharmacology information in drug labelling. Clin. Pharmacol. Ther. 67, 196-200 (2000).
18. Palma, R., Fernandez-Llimos, F. & Rodriguez, L. Accesibilidad de las fichas técnicas españolas por solicitud a la industria farmacéutica. 1st National Congress on Pharmaceutical Care (Colegio de Farmacéuticos, San Sebastian, Spain, 1999).
19. Mashford, M.L. Product information: what does it define? Aust. Prescr. 17, 39-41 (1994).
20. Cohen, J.S. Dose discrepancies between the Physicians' Desk Reference and the medical literature, and their possible role in the high incidence of dose-related adverse drug effects. Arch. Intern. Med. 161, 957-964 (2001).
21. FDA. Code of federal regulations, title 21, Vol. 4, chapter 1. Part 201 - Labeling, http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch. cfm?CFRPart=201&showFR=1&subpartNode=21:4.0.1.1.2.1. Accessed 27 October 2006.
22. Vander Stichele, R., Van Haecht, C.H., Braem, M.D. & Bogaert, M.G. Attitude of the public toward technical package inserts for medication information in Belgium. Ann. Pharmacother. 25, 1002-1006 (1991).
23. Raynor, D.K., Savage, I., Knapp, P. & Henley, J. We are the experts: people with asthma talk about their medicine information needs. Patient Educ. Couns. 53, 167-174 (2004).
24. Dickinson, D., Raynor, D.K., Kennedy, J.G., Bonaccorso, S. & Sturchio, J.L. What information do patients need about medicines? BMJ 327, 861-864 (2003).
25. Graham, J.D. What consumers want to know about medicines. Aust. Prescr. 18, 10-11 (1995).
26. Haefeli, W.E. Verabreichungsfehler - welche informationen braucht ein Patient um seine Arzneimittel-Therapie sicher durchzuführen? Ther. Umsch. 63, 363-365 (2006).
27. Nieminen, O., Kurki, P. & Nordström, K. Differences in product information of biopharmaceuticals in the EU and the USA: implications for product development. Eur. J. Pharm. Biopharm. 60, 319-326 (2005).